Teva launches reformulated levothyroxine range


Teva has introduced a reformulated version of levothyroxine, including two previously unavailable strengths (12.5mcg and 75mcg) that are exclusive to the company.

Authorised for the control of hypothyroidism, congenital hypothyroidism in infants, acquired hypothyroidism in children and juvenile myxedema, the drug is available in the following strengths and pack sizes:

  • 12.5mcg tablets x 28
  • 25mcg tablets x 28
  • 50mcg tablets x 28
  • 75mcg tablets x 28
  • 100mcg tablets x 28.

Bruno Barcelos, senior director, generics, said: “The addition of the exclusive strengths 12.5mcg and 75mcg helps deliver on our commitment to addressing unmet patient needs – and we hope it makes a positive impact on the lives of patients living with underactive thyroid issues.”

The formulation is also lactose- and galactose-free. Underactive thyroid affects 15 in every 1,000 women and one in 1,000 men.

Latest discussions

  1. Pre reg exams

    Thanks for your comments both - Richard ...

  2. Pre reg exams

    Having been qualified just over 40 years...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.